Filing Flows

Filing Flows › Companies › BioCorRx › Cash flow

BioCorRx cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$440K in Q2 2026 · −$2.4M over twelve months

Operating cash flow−$440K
Free cash flow−$440K
Cash conversion cycle-2496 days

Analysis

In Q2 2026, BioCorRx generated −$440K of operating cash flow. That is $314K less than in Q2 2025 (−$126K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$2.4M; the largest uses were operating cash flow ($2.4M); besides operations, cash came from other financing ($2.3M); the cash balance fell by $91K.

Operating cash flow was −$440K against net income of −$1.0M. The largest differences: receivables +$263K, payables +$196K, prepaid and other assets −$175K.

Its cash conversion cycle was -2496 days (receivables 206 + inventory 59 − payables 2760): suppliers fund its working capital.

Free cash flow

BioCorRx: free cash flow by quarterBioCorRx: free cash flow by quarter−$358KQ3 2024−$247KQ4 2024−$690KQ1 2025−$126KQ2 2025−$634KQ3 2025−$848KQ4 2025−$433KQ1 2026−$440KQ2 2026
Operating cash flow less capital spending.
BioCorRx: operating cash flow against capital spendingBioCorRx: operating cash flow against capital spendingOperating cash flowCapital spending−$358K$0Q3 2024−$247K$0Q4 2024−$690K$0Q1 2025−$126K$0Q2 2025−$634K$0Q3 2025−$848K$0Q4 2025−$433K$0Q1 2026−$440K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$440K, Capital spending $0.

Capital allocation, year by year

BioCorRx: where the cash came from (up) and went (down), by fiscal yearBioCorRx: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$3.5MFY2021: Net borrowing $200KFY2021: Shares issued $2.2MFY2021: Capital spending −$2K$2.5MFY2021FY2022: Operating cash flow −$2.0MFY2022: Net borrowing $100KFY2022: Shares issued $1.2M$1.4MFY2022FY2023: Operating cash flow −$1.9MFY2023: Net borrowing $600K$600KFY2023FY2024: Operating cash flow −$1.1MFY2024: Net borrowing $200KFY2024: Shares issued $700K$900KFY2024FY2025: Operating cash flow −$2.3MFY2025
Over these 5 years operating cash flow totalled −$10.8M; the largest uses were operating cash flow ($10.8M) and capital spending ($2K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$21K
Debtnone
Net cash$21K
Cash runway0 months

BioCorRx is burning cash: its operations consume cash, a free cash flow of −$2.4M a year at the current rate against $21K of cash and investments: a runway of about 0 months before any new financing.

Where the cash came from and went

BioCorRx: sources (+) and uses (−) of cash, Q2 2026BioCorRx: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$440KOther financing$250KCash drawn (+) / kept (−)$191K
BioCorRx: sources (+) and uses (−) of cash, TTM to Q2 2026BioCorRx: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$2.4MOther financing$2.3MCash drawn (+) / kept (−)$91K

From profit to cash

BioCorRx: net income to operating cash flow, Q2 2026BioCorRx: net income to operating cash flow, Q2 2026Net income−$1.0MDepreciation & amortization$10KStock-based pay$122KReceivables$263KPayables$196KPrepaid and other assets−$175KOperating cash flow−$440K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026206592760-2496
Q1 202612251314981-14346

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$440K—$191K−$440K
Q1 2026−$433K—−$73K−$433K
Q4 2025−$848K—$148K−$848K
Q3 2025−$634K−$684K−$176K−$634K
Q2 2025−$126K—−$88K−$126K
Q1 2025−$690K$700K$64K−$690K
Q4 2024−$247K$700K−$88K−$247K
Q3 2024−$358K—$8K−$358K

BioCorRx: income statement and cash flow

BioCorRx, Q2 2026: revenue $88K (-51% year over year). The chart follows the revenue to costs, profit and cash.

BioCorRx: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.